Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-11-16 00:00:00 ET · period of report 2023-11-14 · accession 0001628280-23-039300 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-16 | 2023-11-14 | STLN | Virnich Daniel | CEO | D - Sale to Iss | $2.39 | -4,604 | 733.9K | -0.6% | -$11.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-11-14 | D | D | 4,604 | $2.39 | 733,925 | D | — | — |